Our results demonstrated that silenced TG2 combined with p53 in pancreatic cancer cells may cause a specific microenvironment that decreases cell survival in pancreatic β cells in vitro and reduces glucose tolerance in vivo. This evidence concerns the gene TP53 and familial pancreatic carcinoma.